Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 4/20 | 0.72 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | GAPDH | P04406 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 3/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | STAT6 | P42226 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472569 | 1.00 | HSPA8 (0.72) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL7254007 | 0.91 | EGFR (0.60) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL7254000 | 0.90 | HSPA5 (0.59) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL6825589 | 0.85 | HSPA8 (0.61) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1145049 | 0.84 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL17412455 | 0.84 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1145052 | 0.84 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL7258842 | 0.83 | ADORA3 (0.69) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL7258849 | 0.83 | ADORA3 (0.69) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1135195 | 0.83 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412716-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | disclosed |
| US-7163928-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | disclosed |
| US-7144871-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1590359-A2 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV Therapeutics Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004069185-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | HSPA8 1960/4885HSPA5 3596/4885RXFP1 307/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | HSPA8 1960/4885HSPA5 3596/4885RXFP1 307/4885 |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | HSPA8 2241/4885HSPA5 3957/4885RXFP1 294/4885 |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | HSPA8 2062/4885HSPA5 3332/4885RXFP1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.